the health strategist
institute for
health transformation
& digital health
Joaquim Cardoso MSc.
Chief Research and Strategy Officer (CRSO),
Chief Editor and Senior Advisor
September 11, 2023
What is the message?
The article highlights the transformative impact of artificial intelligence (AI) on drug discovery and development, particularly in the Asia-Pacific region.
It underscores how AI technologies have accelerated drug research, significantly reducing costs and timelines, with notable successes during the COVID-19 pandemic.
Additionally, the article emphasizes the importance of AI talent acquisition and international expansion, positioning AI as a pivotal tool in revolutionizing the pharmaceutical industry.
One page summary:
Artificial intelligence (AI) is revolutionizing the field of drug discovery and development, and this article explores its applications in the Asia-Pacific region. In 2018, Google’s DeepMind subsidiary introduced AlphaFold, a program designed to predict protein structures with remarkable accuracy.
Protein structure prediction is a crucial element of drug development, but it has historically been a time-consuming process. AlphaFold’s breakthrough, however, was limited to modeling protein structures, unable to simulate how drugs interact with these proteins. Nevertheless, it sparked a conversation that has led to significant investments in AI-backed drug discovery across Asia and worldwide.
Investments in AI-powered drug discovery have soared over the past four years, reaching an astonishing $24.6 billion in 2022, as reported by Deep Pharma Intelligence. The COVID-19 pandemic played a pivotal role in accelerating the adoption of AI in medication discovery.
Companies like Pfizer collaborated with AI firms to develop COVID-19 treatments in record time, bypassing the conventional, time-intensive vaccine development process. This success highlighted AI’s ability to reduce drug discovery costs and delays by utilizing vast scientific databases, in silico drug candidate screening, and automated data processing.
The traditional drug discovery process is known for its high costs, averaging $1.3 billion and taking a decade to bring a new therapeutic drug to market. With a success rate of less than 10% in clinical trials, eliminating trial and error could save substantial sums and expedite drug development.
Financial analysts project that the adoption of AI may generate significant revenue, with estimates suggesting that up to 50 new AI-driven medicines worth over $50 billion in sales may emerge over the next decade.
Long-term investment in AI-assisted drug design is becoming a strategic focus for companies like Huawei Cloud. Their Pangu Drug Molecule Model, developed in collaboration with the Shanghai Institute of Materia Medica, streamlines drug discovery by using data from over 1.7 billion compounds.
AI’s potential to reduce R&D costs by up to 70% and expedite the discovery of novel lead compounds from months to years holds great promise for the pharmaceutical industry.
Huawei’s success has led to the launch of an AI-assisted commercial pharmaceutical Software as a Service (SaaS) platform in China, aimed at reducing the costs of trial and error while accelerating lead compound discovery. This platform is set to expand internationally, starting with the Asia-Pacific region and the Middle East.
AI applications in drug discovery are changing the landscape of talent requirements in the pharmaceutical industry. China, in particular, leads the global AI industry, with over 60% of big data experts across various sectors.
As AI becomes increasingly integral to healthcare, companies are preparing for a talent gap, leading to collaboration or acquisition strategies similar to those of Sanofi, Merck, and GSK.
Singapore has emerged as a hub for AI, robotics, and pharmaceutical manufacturing, hosting 30 contract manufacturing facilities, mostly foreign-owned. Companies like Merck, Novartis, and GSK have recognized the potential in Singapore’s growing ecosystem.
Japan’s Takeda Pharmaceutical has also embraced AI, partnering with AI tech startups and hiring additional data scientists to expedite medication development. Their recent acquisition of AI startup Nimbus Therapeutics for $4 billion demonstrates AI’s potential.
Nimbus Therapeutics employed AI and machine learning algorithms to identify a compound to treat psoriasis, which has already passed the initial phases of human trials.
AI is reshaping drug discovery by extracting hidden patterns from extensive biomedical data, improving the clinical trial process, and repurposing existing drugs for new applications, ultimately bringing treatments to patients more rapidly.
DEEP DIVE
Wonder drugs in the AI age: The Asian advantage
AI is speeding up drug discovery and development. Here is a look at its applications in Asia Pacific (Image via Canva Pro)
Omnia Health
Praseeda Nair
August 22, 2023
In 2018, long before the artificial intelligence (AI) bandwagon started careening down the mainstream, DeepMind, a subsidiary of Google parent Alphabet, developed a program named AlphaFold to predict protein structures faster and more accurately than biologists. Predicting protein shapes is a key aspect of drug development, disease treatment, and treatment research, but it is a traditionally long and arduous process. Faster, more affordable medication may soon be within reach thanks to AI automation across the entire drug development pipeline.
However, even this promised panacea had its Achilles’ heel. MIT researchers found that AlphaFold is only concretely useful in one step of drug discovery: modelling the structure of the protein. The system cannot model how a drug physically interacts with the protein. AlphaFold may not be a catch-all in drug discovery, but it started a conversation that is now funnelling millions of dollars in investment into key markets across Asia and beyond. According to Deep Pharma Intelligence, investments in AI-backed drug discovery have tripled over the last four years, reaching a staggering US$24.6 billion in 2022.
The post-COVID-19 factor
During the pandemic, economies worldwide relied on AI-based medication discovery rather than traditional vaccine detection processes, which take years to create and are equally expensive, contributing to the market’s growth. For example, Pfizer collaborated with AI businesses to develop COVID therapies, which were approved in less than two years, compared to the typical 10-year process.
By using big scientific databases, reviewing drug candidates in silico, and expediting high-content screening tests with automated data processing, AI has proven its mettle in cutting drug discovery costs and delays. Now, the industry is making strategic decisions to bounce back post-COVID-19 through a big R&D push to bring advanced and accurate AI software to the market.
The current drug discovery process involves a time-consuming and costly trial-and-error approach. It costs approximately US$1.3 billion and 10 years to bring a new therapeutic drug to market, and this cost is expected to rise.
Clinical trials also have a notoriously high rate of failure — over 90 per cent by some estimates — which means eliminating trial and error might save businesses a lot of money while getting drugs from the lab to market more quickly.
The potential revenue is enormous; financial analysts at Jeffries estimate that Takeda’s move may generate up to US$3.7 billion in annual sales. Morgan Stanley estimates that the next 10 years may spawn up to 50 new AI-driven medicines worth more than US$50 billion in sales.
AI is a long-term strategy
Huawei Cloud is adopting a long-term investment strategy in AI-assisted drug design. The Huawei Cloud Pangu Drug Molecule Model, developed with the Shanghai Institute of Materia Medica, helps pharmaceutical companies build small[1]molecule drugs. The model uses data from over 1.7 billion compounds to streamline the process for researchers to then run targeted experiments to verify efficacy.
“AI could effectively function as a virtual chemist, helping researchers design and identify novel molecules that are likely to interact with drug targets,” says Dr. Qiao Nan, Head of Huawei Cloud EI Health.
According to Qiao, AI could shrink R&D costs by up to 70 per cent while helping scientists discover novel lead compounds in months rather than years.
“This would make more potential drug candidates available for clinical trials, lifting the overall success rate in what traditionally has been hit-or-miss process and increasing the odds that a new chemical compound will eventually become an effective, life-saving drug.”
On the back of this success, Huawei launched a unique AI-assisted commercial pharmaceutical SaaS platform in China to help companies reduce the costs of trial and error, while accelerating the discovery of lead compounds from several years to just one month. The SaaS platform is slated to expand internationally, starting with APAC, the Middle East, and further afield.
Building a strong AI talent pipeline
AI applications lower the R&D gap in the drug manufacturing process and aid in targeted medication manufacturing. As a result, biopharmaceutical companies are turning to AI to increase their market share. However, AI for drug discovery requires machines to replicate human intellect to address complex drug development difficulties — a tall order for any platform that is meant to be a tool. Its success depends on how and by whom it is used.
Currently, China is leading the global AI industry, housing over 60 per cent of big data experts across sectors. As more industry segments begin to rely on AI, players in healthcare will need to start preparing for a gap between supply and demand for talent. The alternative, as seen by incumbents including Sanofi, Merck, and GSK, is growth through collaboration or acquisition.
As the demand for messenger RNA (mRNA) vaccines in Southeast Asia increased during the pandemic, Singapore quickly established itself as a hub for AI, robotics, and manufacturing for leading pharmaceutical companies to open their regional headquarters. The small city-state is home to 30 contract manufacturing facilities, most of which are foreign-owned, if not partially backed.
According to GlobalData’s Contract Service Provider database, Merck currently owns three facilities in Singapore, and Novartis and GSK each own two facilities. “New opportunities will emerge as the biomanufacturing industry undergoes major changes brought about by the rapid pace of digitalisation, Industry 4.0, and the need for greater sustainability,” says Lim Keng Hui, Assistant Chief Executive of Singapore’s Science and Engineering Research Council, A*STAR.
Recently, Japan’s Takeda Pharmaceutical has partnered with AI tech startups and hired additional data scientists to address this. AI is part of Takeda’s long-term strategy to save money and time by speeding up the medication development process.
In May, the global pharma giant acquired US-based AI startup Nimbus Therapeutics for US$4 billion. The start-up used AI and machine learning algorithms to pick a compound to treat psoriasis out of thousands of other molecules. The experimental drug has already passed the first two phases of human trials, meaning it could be one of the first therapies discovered with AI if it passes the final trials this year. AI is shifting the drug discovery paradigm by extracting hidden patterns and evidence from vast biomedical data, dramatically improving the clinical trial process while mining old drugs for new applications. The result is expected to bring treatments to patients faster.
Originally published at https://insights.omnia-health.com
